Pure Transplant Solutions, LLC (PTS) is a biotechnology company whose goal is to reduce and potentially eliminate both chronic and acute Antibody Remediated Rejection (AMR) in organ transplants (including kidney, liver, heart, lung and pancreas) and in tissue transplants.
Complications arising from Human Leukocyte Antigen (HLA) antibody incompatibility are a cause for both acute and chronic AMR. PTS, in collaboration with the University of Oklahoma Health Sciences Center, is harnessing over a decade of groundbreaking research in HLA proteins to deliver novel and patient specific immunotherapeutic and diagnostic products. PTS expects these products will be the first and only products that identify and remove only the patient’s Donor Specific Antibodies (DSA) without compromising their immune system.
The initial application is for reducing post-transplant chronic AMR in kidney transplants patients.
About Us
Pure Transplant Solutions was founded in 1999 in order to leverage leading research in HLA protein into solutions to address a growing list of needs in organ transplantation. The unique solutions offered by Pure Transplant are based on technology discovered by Chief Scientist Dr. William Hildebrand at the University of Oklahoma Health Sciences Center.
Pure Transplant Solutions is a portfolio company of leading life sciences technology management firm Emergent Technologies, Inc. with business operations based in Austin, TX and research, development and production facilities in Oklahoma City, OK.
Pure Transplant Solutions is a portfolio company of leading life sciences technology management firm Emergent Technologies, Inc. with business operations based in Austin, TX and research, development and production facilities in Oklahoma City, OK.
Technology
The human immune system is complex and diverse. Most companies have not been able to deal with its intricacies, seeking broad spectrum remedies that are incapable of specifically addressing the wide variety of security breaches each system faces without damaging parts of the security system that are essential for survival. But Pure Transplant Solutions (PTS) has, and that’s why we are far ahead of the pack in harnessing the power of the body’s immune system.
Our use of natural, high-quality HLA components are critical to the immune system’s fine-tuned receptors, which are quick to reject non-self organs and foreign infectious agents. Because we synthesize our HLA proteins in mammalian cells instead of insect or bacterial cells, our technologies circumvent the purification and production issues afflicting our competitors. And we are able to control the body’s immune system responses more effectively and efficiently.
PTS' goal is to reduce and potentially eliminate both chronic and acute Antibody Remediated Rejection (AMR) in organ transplants (including kidney, liver, heart, lung and pancreas) and in tissue transplants. This may extend the lifetime of organ grafts to existing transplant patients. It may also enable significantly more transplants by removing the major bottleneck in HLA matching between donors and patients.
Both chronic and acute AMR is dependent primarily on Donor Specific Antibodies in the patient that has been sensitized to specific Human Leukocyte Antigen (HLA) in the donor organ. PTS is developing a revolutionary therapeutic Selective HLA Antibody Removal System (SHARC) that removes only the specific DSA that will cause AMR. A long term goal is to enable any patient to accept any donor organ regardless of HLA match removing bottleneck in organ transplants.
Our use of natural, high-quality HLA components are critical to the immune system’s fine-tuned receptors, which are quick to reject non-self organs and foreign infectious agents. Because we synthesize our HLA proteins in mammalian cells instead of insect or bacterial cells, our technologies circumvent the purification and production issues afflicting our competitors. And we are able to control the body’s immune system responses more effectively and efficiently.
PTS' goal is to reduce and potentially eliminate both chronic and acute Antibody Remediated Rejection (AMR) in organ transplants (including kidney, liver, heart, lung and pancreas) and in tissue transplants. This may extend the lifetime of organ grafts to existing transplant patients. It may also enable significantly more transplants by removing the major bottleneck in HLA matching between donors and patients.
Both chronic and acute AMR is dependent primarily on Donor Specific Antibodies in the patient that has been sensitized to specific Human Leukocyte Antigen (HLA) in the donor organ. PTS is developing a revolutionary therapeutic Selective HLA Antibody Removal System (SHARC) that removes only the specific DSA that will cause AMR. A long term goal is to enable any patient to accept any donor organ regardless of HLA match removing bottleneck in organ transplants.
SHARC – Selective HLA Antibody Removal Column
PTS integrates its patented sHLA protein into a combination medical device for use in a novel selective antibody removal therapy. This immunotherapeutic device is called the Selective HLA Antibody Removal Column (SHARC). SHARC therapy is similar to that of plasmapheresis therapy with the distinct difference of removing only those selected DSAs as opposed to the removal of all antibodies present.
SHLA CHIP MICROASSAY
Pure Transplant Solutions is developing a sHLA chip companion diagnostic for antibody-screening to provide a precise method for determining the presence of anti-HLA antibodies in transplant recipients as well as the exact HLA specificity of those antibodies. Combined with the SHARC, PTS aims to provide a comprehensive screening and therapeutic solution for targeted HLA antibody detection and removal.
Initial patient populations to benefit from SHARC therapy will be those experiencing chronic AMR where the removal of DSAs will increase the lifetime of an organ and in turn, will reduce the number of patients in need of re-transplantation and/or dialysis therapy. PTS envisions the use of SHARC for additional patient populations including those with acute AMR as well as those unable to receive an organ as a result of HLA incompatibility. In doing so, PTS aims to dramatically increase the number of patients benefiting from organ transplants.
Specificity: Only harmful antibodies removed; concomitant immunosuppressive Mab Rx therapy unaffected
Safety: Humoral immune system remains intact
Tolerance: No serum proteins removed resulting in normal coagulation & CV stability
Effectiveness: Up to 80% of harmful antibodies removed in a single treatment; may be performed pre- and post- transplant.
Advantages
Only SHARC addresses the root cause of many transplant rejections: anti-HLA Donor Specific AntibodiesSpecificity: Only harmful antibodies removed; concomitant immunosuppressive Mab Rx therapy unaffected
Safety: Humoral immune system remains intact
Tolerance: No serum proteins removed resulting in normal coagulation & CV stability
Effectiveness: Up to 80% of harmful antibodies removed in a single treatment; may be performed pre- and post- transplant.
Therapeutic
Specificity: SHARC will target and remove only the problematic HLA antibodies. Beneficial antibodies, such as virus-specific and anti-idiotype antibodies are not removed.
Tolerability: SHARC will not remove proteins required for normal coagulation and cardiovascular stability.
Effectiveness: SHARC removes a large proportion of targeted antibodies in a single session and with good tolerability, can be effective for prolonged and repeat treatments.
Safety: SHARC will leave the patient's immune system intact while removing problematic DSAs. In doing so, antibacterial, antifungal and antiviral antibodies remain intact and available to combat infection.
Diagnostic
Utilizing proprietary technology, Pure Transplant Solutions is working with industry partners to develop screening assays in order to prevent the rejection of organs in the growing field of organ transplant matching. Combined with the SHARC, Pure Transplant Solutions aims to provide a comprehensive, targeted solution in HLA antibody mediated rejection.
Advantages:
- Improved Dynamic Range, SNR, speed and ease of use
- Provides critical clinical information for targeted SHARC therapy
News
February 15, 2022 - Pure Transplant Solutions, LLC and Vall d’Hebron University Hospital Announce Research Collaboration Developing New Technologies & Diagnostic Tools for B-Cell Monitoring in Transplant Rejection
December 7, 2021 -Pure Transplant Solutions, LLC and Oxford Immunotec, Ltd. Announce Exclusive Sublicense Agreement to Support Commercialization of Novel B Cell Measurement Assay for Early Detection of Tissue Injury and Prevention of Organ Rejection
July 21, 2021 - Pure Transplant Solutions, LLC Announces Research Collaboration with the Department of Surgery at the University of Cambridge
March 24, 2021 - Pure Transplant Solutions Announces Collaboration with Innobiochips to Develop Personalized Diagnostics for Post-Transplant Monitoring and Early Detection of Transplant Rejection
March 17, 2021 - Pure Transplant Solutions Announces Collaboration with Northwestern University to Develop Novel Reagents for Enhanced Characterization of HLA DQ Antigens In Transplant Rejection
March 11, 2021 - Pure Transplant Solutions Announces Collaboration with the University of Alabama at Birmingham to Develop Memory B Cell-Directed Diagnostics for HLA-Sensitized Patients
February 24, 2021 - Pure Transplant Solutions Announces Collaboration with King’s College London to Support NHS Funded GAMECHANgER-1 Clinical Trial for HLA Sensitized Patients with End Stage Renal Disease
February 4, 2021 - Pure Protein, LLC and Pure Transplant Solutions, LLC Promote Blake Harlan to President and Dr. Rico Buchli to Vice President of Products and Service
January 27, 2021 - Pure Transplant Solutions, LLC and University Hospital Basel Announce Research Collaboration
February 13, 2019 - Emergent Technologies, Inc. Hires Steven Lloyd Mayer, MD as Chief Medical Officer and Promotes Blake Harlan to Executive Vice President Finance and Operations
April 5, 2016 - GMS Biotech and Pure Protein Awarded Two Year $2,609,551 SBIR Grant to Develop sHLA Protein Chip for Anti-HLA Antibody Screening & Monitoring
.
December 7, 2021 -Pure Transplant Solutions, LLC and Oxford Immunotec, Ltd. Announce Exclusive Sublicense Agreement to Support Commercialization of Novel B Cell Measurement Assay for Early Detection of Tissue Injury and Prevention of Organ Rejection
July 21, 2021 - Pure Transplant Solutions, LLC Announces Research Collaboration with the Department of Surgery at the University of Cambridge
March 24, 2021 - Pure Transplant Solutions Announces Collaboration with Innobiochips to Develop Personalized Diagnostics for Post-Transplant Monitoring and Early Detection of Transplant Rejection
March 17, 2021 - Pure Transplant Solutions Announces Collaboration with Northwestern University to Develop Novel Reagents for Enhanced Characterization of HLA DQ Antigens In Transplant Rejection
March 11, 2021 - Pure Transplant Solutions Announces Collaboration with the University of Alabama at Birmingham to Develop Memory B Cell-Directed Diagnostics for HLA-Sensitized Patients
February 24, 2021 - Pure Transplant Solutions Announces Collaboration with King’s College London to Support NHS Funded GAMECHANgER-1 Clinical Trial for HLA Sensitized Patients with End Stage Renal Disease
February 4, 2021 - Pure Protein, LLC and Pure Transplant Solutions, LLC Promote Blake Harlan to President and Dr. Rico Buchli to Vice President of Products and Service
January 27, 2021 - Pure Transplant Solutions, LLC and University Hospital Basel Announce Research Collaboration
February 13, 2019 - Emergent Technologies, Inc. Hires Steven Lloyd Mayer, MD as Chief Medical Officer and Promotes Blake Harlan to Executive Vice President Finance and Operations
April 5, 2016 - GMS Biotech and Pure Protein Awarded Two Year $2,609,551 SBIR Grant to Develop sHLA Protein Chip for Anti-HLA Antibody Screening & Monitoring
.
Contact Us
Pure Transplant Solutions
Managed by Emergent Technologies, Inc.
7500 Rialto Blvd.,
Building 2, Suite 260
Austin, Texas 78735
Phone: (512) 263-3232
Fax: (512) 263-3236
Email: info@puretransplant.com
